^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Peritoneal Cancer |
| Drug: | sorafenib (Multi-tyrosine kinase inhibitor, pan-RAF inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
Acceptable Recurrence Therapies for…Peritoneal Cancer: Other Recommended Regimen...Sorafenib/Topotecan
Secondary therapy:
topotecan
